Zobrazeno 1 - 10
of 174
pro vyhledávání: '"E. D., Crawford"'
Autor:
P. S. Ramachandran, A. Ramesh, F. V. Creswell, A. Wapniarski, R. Narendra, C. M. Quinn, E. B. Tran, M. K. Rutakingirwa, A. S. Bangdiwala, E. Kagimu, K. T. Kandole, K. C. Zorn, L. Tugume, J. Kasibante, K. Ssebambulidde, M. Okirwoth, N. C. Bahr, A. Musubire, C. P. Skipper, C. Fouassier, A. Lyden, P. Serpa, G. Castaneda, S. Caldera, V. Ahyong, J. L. DeRisi, C. Langelier, E. D. Crawford, D. R. Boulware, D. B. Meya, M. R. Wilson
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Tuberculous meningitis is difficult to differentiate from meningitis caused by other pathogens. Here, the authors combine metagenomics-based pathogen detection in cerebrospinal fluid with a host gene expression-based machine learning classifier for d
Externí odkaz:
https://doaj.org/article/867461ee71554502b141c59c90a9fca9
Autor:
E. Rackaityte, J. Halkias, E. M. Fukui, V. F. Mendoza, C. Hayzelden, E. D. Crawford, K. E. Fujimura, T. D. Burt, S. V. Lynch
Publikováno v:
Microbiome, Vol 9, Iss 1, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/69f6d1b3d28a4531ba8dd825d47090c6
Autor:
Louis Denis, Brent A. Blumenstein, P Iversen, R Hall, E. D. Crawford, Catherine Hill, Richard Sylvester, H. van Tinteren, Fritz H. Schröder, Mike Clarke, Otilia Dalesio, Jon Godwin, W U Shipley, M. Soloway, Richard Peto, I Dechering, Collaborat Pct., V Evans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60213558e6d17fcfcdedbe699c8def0
https://ora.ox.ac.uk/objects/uuid:422f4aed-9906-4b55-b199-a99d24dc6211
https://ora.ox.ac.uk/objects/uuid:422f4aed-9906-4b55-b199-a99d24dc6211
Publikováno v:
International Journal of Clinical Practice. 65:1180-1192
SUMMARY Background: Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer associated with poor survival rates. However, characterisation of the disease epidemiology is hampered by use of varying terminology, definition an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b52fa0e3c7c438e49cd83a1912ddd59
https://doi.org/10.1111/j.1742-1241.2011.02799.x
https://doi.org/10.1111/j.1742-1241.2011.02799.x
Publikováno v:
International Journal of Impotence Research. 21:9-23
This paper provides a systematic review of the literature about prostate cancer risk associated with testosterone therapy for hypogonadism. A comprehensive search of MEDLINE, EMBASE and other resources was conducted to identify articles that highligh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e33d2395145fbf8927d299f29ffa5f9
https://doi.org/10.1038/ijir.2008.31
https://doi.org/10.1038/ijir.2008.31
Publikováno v:
BJU International. 92:695-698
OBJECTIVE To investigate the efficacy of low-dose flutamide (125 mg twice daily) in the treatment of prostate-specific antigen (PSA) recurrence after definitive treatment with radical retropubic prostatectomy (RRP), external-beam radiation therapy (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70f43a7bdd0295e17dc237895a6032c9
https://doi.org/10.1046/j.1464-410x.2003.04479.x
https://doi.org/10.1046/j.1464-410x.2003.04479.x
Autor:
J Presti, Gerald W. Chodak, E D Crawford, Michael F. Sarosdy, P Mitchell, Paul F. Schellhammer, Mark S. Soloway, Nicholas J. Vogelzang, Laura S. Porter
Publikováno v:
BJU International. 83:801-806
Objective To determine the endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of Zoladex™(goserelin acetate, Zeneca Pharmaceuticals, Wilmington, Delaware, USA), a luteinizing hormone-releasing hormone agonist analogue, when
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0a36ec34fd7272c143b6c82f5d49154
https://doi.org/10.1046/j.1464-410x.1999.00028.x
https://doi.org/10.1046/j.1464-410x.1999.00028.x
Publikováno v:
Prostate Cancer and Prostatic Diseases. 2:172-179
Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::642c3bb2b0f49d83c5639b2839e08d86
https://doi.org/10.1038/sj.pcan.4500323
https://doi.org/10.1038/sj.pcan.4500323
Autor:
S Leewansangtong, E D Crawford
Publikováno v:
Endocrine Related Cancer. 5:325-339
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c97e60cd7629ff85df16e4331f26924d
https://doi.org/10.1677/erc.0.0050325
https://doi.org/10.1677/erc.0.0050325
Autor:
Perry B. Hudson, J. Waldstreicher, H. A. Guess, Gerald L. Andriole, L. Patterson, N. A. Romas, Jonathan I. Epstein, C. L. Jackson, T. J. Cook, E. D. Crawford, D. Kadmon, H. Wise
Publikováno v:
Urology. 52:195-202
Objectives. To evaluate prostate cancer detection and prostate-specific antigen (PSA) among men with benign prostatic hyperplasia treated with finasteride. Methods. Three thousand forty men 45 to 78 years of age with PSA less than 10 ng/mL and no his
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::784f2b29dbe3558a66b13ed994622397
https://doi.org/10.1016/s0090-4295(98)00184-8
https://doi.org/10.1016/s0090-4295(98)00184-8